BioVie Spinoff Liver Disease Drug Company Option Therapeutics(OPTN.US)Reduces IPO Size, Cuts Fundraising Target by 20% to $20 Million

LootboxPhobia · 2026-03-17T09:14:08+00:00

Option Therapeutics plans to reduce its IPO size and raise $20 million by issuing 1.8 million shares at a price range of $10 to $12 per share, representing a 20% decrease from previous expectations. The company focuses on treating serious liver diseases and has not yet generated revenue. Founded in 2025, it plans to list on the New York Stock Exchange under the ticker symbol OPTN.

LootboxPhobia

2026-03-17 09:14:08

Abstract generation in progress

The Tongbao Finance APP has learned that on Monday, the clinical stage liver disease biotech company Option Therapeutics (OPTN.US), spun off from BioVie, reduced the size of its upcoming IPO. The company, headquartered in Carson City, Nevada, now plans to raise $20 million by issuing 1.8 million shares at a price range of $10 to $12. Previously, the company had applied to issue 2.3 million shares within the same range. Based on the midpoint of the price range, Option Therapeutics’ fundraising amount will be 20% less than previously expected.

The company focuses on developing candidate drugs for the treatment of severe and life-threatening liver diseases. Its lead product, BIV201, is currently being evaluated for treating complications related to advanced cirrhosis and has filed patent applications in the United States, China, Japan, Chile, and India. Option Therapeutics has not yet generated revenue.

Founded in 2025, Option Therapeutics plans to list on the NYSE American, with the stock ticker OPTN. ThinkEquity is serving as the exclusive bookrunner for the transaction.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.